Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry - ScienceDirect
Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
PDF) Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor
MORE
Cell-active, irreversible covalent inhibitors that selectively target the catalytic lysine of EGFR by using fluorosulfate-based SuFEx chemistry - ScienceDirect
High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib - JTO Clinical and Research Reports
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs - ScienceDirect
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and
Patient Identification – TAGRISSO® (osimertinib) Nurse Center
/cdn.vox-cdn.com/uploads/chorus_image/image/25074845/gyi0062918183.0.jpg)
